MSMassimiliano Spada

Massimiliano Spada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Massimiliano Spada has a total of 162 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Review of: "Sotorasib Treatment Could Worsen the Prognosis of Advanced KRASG12C-Mutated Non-Small Cell Lung Cancer"

    by Massimiliano Spada

    I believe it is appropriate to focus on the choice of drug used in the control arm: docetaxel is not the first option in many countries, especially European ones, due to its toxicity. I believe this in-depth analysis can give even more value to the a...

  • Five-Fraction Stereotactic Radiotherapy for Brain Metastases: A Single-Institution Experience on Different Dose Schedules

    by Antonio Piras, Luca Boldrini, Sebastiano Menna, Antonella Sanfratello, Andrea D’aViero, Davide Cusumano, Luciana Di Cristina, Marco Messina, Massimiliano Spada, Tommaso Angileri, et al.

    Introduction: The most common intracranial neoplasm diagnosed in adults are brain metastases (BrM). The benefit in terms of clinical control and toxicity for stereotactic radiotherapy (SRT) has been investigated for patients with low load of BrM. Aim: The aim of this single-institution experience was to investigate the best dose schedule for five-fraction SRT (FFSRT). Methods: A retrospective analysis of patients treated for BrM with different dose schedules of FFSRT was performed. Local control (LC) and clinical outcomes were evaluated with magnetic resonance imaging at 3, 6, and 9 months. Toxicity data were also collected. Results: A total of 41 patients treated from November 2016 to September 2020 were enrolled in the analysis. Non-small cell lung cancer (51.2%) and breast cancer (24.3%) represented the most frequent primitive tumors. Treatment was performed on 5 consecutive days with prescribed dose ranging from 30 to 40 Gy, prescribed to the 95% isodose line that covered at least 98% of the gross tumor volume. Statistically significant differences (p = 0.025) with higher LC rates for dose schedules >6 Gy for fractions. Toxicity rates were not found to be higher than G1. Conclusion: The results of this retrospective analysis suggest that FFSRT for BrM seems to be safe and feasible. Our results also underline that a total dose lower than 30 Gy in 5 fractions should not be used due to the expected minor LC.


  • Management of Patients with Gastric or Gastroesophageal Junction Cancer: From Theory to Integrated Clinical Path- ways Implementation in the Real World.

    by R Guggino, N Borsellino, M Spada, F Verderame, P Mezzatesta, P Marchesa, A Firenze, F Cartabellotta, I Fazio, S Pergolizzi, et al.

    Best care of esophagogastric junction and gastric cancer (EGC) requires a complex, timely interaction between members of a multi-disciplinary team (MDT). An integrated clinical pathway (ICP) is necessary to achieve this goal as well as the implementation of its use in daily practice. The objective of this study was to elaborate on an integrated clinical pathway for the multi-disciplinary management of ECG. Authors also put in act an implementation program to improve adherence to guidelines thought an ICP. This prospective work carried out by a multi-institutional MDT in Italy identified expert panel extracted relevant recommendations and/or statements from published papers and guidelines obtaining a set of crucial interventions employed the Estimate-Talk-Estimate method. A flow-chart diagram was elaborated to elicit the process at a glance. The primary outcome measure was the elaboration of an ICP with a high consensus rate also reported as a snapshot diagram and its implementation in daily clinical practice. An accredited certification body agency validated results, and an implementation process was started in several hospitals known to treat ECG. A methodologist aggregated a multi-disciplinary panel of experts from different institutions. The panel elaborated a flow-chart diagram with crucial intervention highlight and connecting lines, as well as outcome measures. An accredited certification body agency validated the entire process, representing the basis for empowerment and implementation among patients and oncological professionals in various hospitals. The multi-disciplinary and multi-institutional expert panel successfully elaborated on a validated ICP for all stages ECG. An in-hospital implementation program has been programmed.

  • Sequencing Radium 223 and Other Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients

    by Orazio Caffo, Viviana Frantellizzi, Fabio Monari, Andrea Sbrana, Renato Patrizio Costa, Carmine Pinto, Marcello Tucci, Sergio Baldari, Gaetano Facchini, Roberto Bortolus, et al.

    Background: Radium 223 (RA223) is currently administered as part of a therapeutic sequence with the other life-prolonging agents (LPAs) for metastatic castration-resistant prostate cancer (mCRPC). ...


  • Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study

    by Maria Di Bartolomeo, Monica Niger, Giuseppe Tirino, Angelica Petrillo, Rosa Berenato, Maria Maddalena Laterza, Filippo Pietrantonio, Federica Morano, Maria Antista, Sara Lonardi, et al.

    Ramucirumab—alone or combined with paclitaxel—represents one of the main options for patients failing first-line treatment for advanced gastric cancer.


  • Minimally invasive surgical approach for radicalization of incidental post-cholecystectomy gallbladder carcinoma: safety, feasibility and outcomes

    by Emanuele Sinagra, Stefano Garritano, Salvatore Marco Iacopinelli, Marco Messina, Dario Raimondo, Francesca Rossi, Massimiliano Spada, Guido Martorana, Marcello Giuseppe Spampinato

    Background and aims: Gallbladder carcinoma is a rare but aggressive malignant neoplasm. The incidence of intra- or post-operative incidental gallbladder carcinoma diagnosis following laparoscopic cholecystectomy is estimated to be 1–2%. Aggressive re-resection is warranted as the majority of patients have residual disease either in the liver or the lymph nodes. However the use of a minimally invasive surgical approach (MISA) to perform a radicalization in these patients has not been investigated yet. We retrospectively analyzed surgical and oncologic outcome of a small selected cohort of patients with incidental gallbladder carcinoma whom underwent redo radicalization surgery by MISA. Material and methods: From April 2012 to June 2014 at our department six patients (three females and three males) with incidental findings of gallbladder carcinoma pT1b (stage I) following laparoscopic cholecystectomy, and referred to our center from other secondary-level referral hospitals, underwent a redo surgery for radicalization by means of laparoscopic (n. 3) or robotic approach (n. 3). A retrospective analysis of prospective collected data was performed. Results: The redo procedure consisted of a liver resection (segments IVb + V) and lymph nodes clearance of hepatoduodenal hilum and common hepatic artery. Conversion rate was zero. Median operative time was 290 (250–310) min. Estimate blood loss was 175 (100–350) ml. Total hospital stay was 6 (5–10) days. All liver resections were performed without inflow vascular clamping. One patient was re-operated for hemoperitoneum while peri-operative mortality was zero. Oncologically, an R0 resection was always achieved with a mean number of lymph nodes retrieved of 17,5 (14–22). The stage of the neoplasm was confirmed in all cases but one, who was found to have a pN1 status (stage IIIb). At 21 (6–32) months follow-up all patients are alive and no recurrence has been observed. Conclusions: Our data suggest that radicalization of patients with stage I incidental postoperative gallbladder carcinoma can be done by a MISA without compromising the oncologic outcome. Larger studies are needed to validate these results.


    • 1 October 2017
      • Vol. 31  (4) , 1101-1107

    COLORECTAL CANCER IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SINGLE-CENTER EXPERIENCE

    by E. Sinagra, V. Guarnotta, D. Raimondo, F. Mocciaro, S. Dolcimascolo, C. A. Rizzolo, F. Puccia, N. Maltese, R. Citarrella, M. Messina, et al.

    Type 2 diabetes mellitus (T2DM) is associated with an increased risk of colorectal cancer (CRC). The aim of the study is to evaluate the prevalence of CRC in a cohort of Caucasian patients with T2DM and the association with other variables previously known to be related with increased risk of CRC. We retrospectively evaluated the data of 741 consecutive Caucasian patients with T2DM who underwent colonoscopic screening in our tertiary referral center. A control cohort of 333 patients with thyroid disease was selected to evaluate the difference in the incidence of CRC. At a median follow-up of 132.5 months (range 33.3-175.7), 67 cases of cancer (prevalence 9%) occurred; among these, 14 cases of CRC were reported (prevalence 1.88%) among the diabetic patients, while only two case (one of these was a CRC) (overall prevalence 0.006%, prevalence of CRC 0.003%) occurred in the control group; the difference between the prevalence of CRC was statistically significant (chi-square 4.21, p = 0.04). The median duration of T2DM to CRC diagnosis was 168 months (range 12-768). At the univariate analysis, older age (p = 0.001, r 0.138) and diabetes duration (p = 0.001, r 0.138) were related to higher risk of cancer, while metformin seems to be protective towards cancer (p = 0.07, r - 0.098). In the subset of patients with CRC, the age (RR = 2.25; 95% CI: 0.30 - 17.31; p < 0.001), the diabetes duration (RR = 1.93; 95% CI: 0.25 - 14.77; p = 0.001) and the sulphonylureas treatment (RR = 2.33; 95% CI: 0.78 - 7.38; p = 0.007) were independently correlated with CRC. In our study, the prevalence of CRC in the cohort of patients with T2DM was higher compared to that from the National Tumor Register in 2010 (0.5%). Furthermore, we could speculate that sulphonylureas may play a role in CRC carcinogenesis impairing the physiological insulin secretion.


  • JC Virus and Lung Adenocarcinoma: Fact or Myth?

    by Emanuele Sinagra, Dario Raimondo, Elena Gallo, Mario Stella, Mario Cottone, Francesca Rossi, Marco Messina, Massimiliano Spada, Giovanni Tomasello, Giuseppe Ferrara, et al.

    Background/Aim: An association has been reported between lung cancer and John Cunningham (JC) virus infection. The aim of this study was to evaluate the prevalence of JC virus in a small cohort of patients with lung adenocarcinoma and assess its presence in nodal metastasis. Materials and Methods: Consecutive samples of 13 surgically-removed lung tumors and 13 surrounding normal cancer-free tissues were selected. Five cases included metastatic lymph nodes. JC virus infection was assessed through nested PCR. Results: Seven out of thirteen patients with lung adenocarcinoma had a positive PCR test for JC virus. One of the five patients with nodal metastasis had a positive PCR test for JC virus. None of the thirteen specimens from the control group presented with JC virus infection. The difference between the two groups regarding JC virus infection was statistically significant (p=0.008). Conclusion: Our study suggests that JC virus might be involved in lung carcinogenesis.


  • Palexia crystals in gastrointestinal tract, a new entity associated with death following gastrointestinal hemorrhage

    by Marco Calvaruso, Emanuele Sinagra, Massimo Castellucci, Massimiliano Spada, Dario Raimondo, Aroldo Gabriele Rizzo


  • An unusual presentation of unresectable gastric cancer in a young woman, treated with palliative endoscopic treatment with triple metal stents

    by Dario Raimondo, Emanuele Sinagra, Tiziana Facella, Francesca Rossi, Simona Di Caro, Massimiliano Spada, Guido Martorana, Vincenzo Mastrella, Ennio La Rocca